Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion–Mutated Advanced NSCLC: Primary Results From PAPILLON, a Randomized Phase 3 Global Study | OncLive
13:44
Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Tre…
Nov 30, 2023
onclive.com
PAPILLON Study - Amivantamab Chemo vs. Chemo as 1L Treatment in EGFR Exon 20 Insertion-Mutated Advanced NSCLC
PAPILLON Study - Amivantamab Chemo vs. Chemo as 1L Treatmen…
Feb 12, 2024
vumedi.com
The Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC Management | OncLive
The Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCL…
2 months ago
onclive.com
Implications of the FDA Approval of Subcutaneous Amivantamab in EGFR-Mutated NSCLC | OncLive
Implications of the FDA Approval of Subcutaneous Amivantamab in E…
1 month ago
onclive.com
Predictive Biomarkers for Treatment With Amivantamab Plus Lazertinib Among EGFR-Mutated NSCLC in the Post-Osimertinib Setting: Analysis of Tissue IHC and ctDNA NGS | OncLive
1:14
Predictive Biomarkers for Treatment With Amivantamab Plus Lazertini…
Apr 29, 2024
onclive.com
Dr Leighl on Amivantamab in Advanced NSCLC With MET Exon 14 Skipping Mutations | OncLive
Dr Leighl on Amivantamab in Advanced NSCLC With MET Exon …
Sep 12, 2023
onclive.com
PAPILLON: amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions
2:07
PAPILLON: amivantamab plus chemotherapy in NSCLC with EGF…
421 viewsMay 13, 2024
YouTubeVJOncology
6:53
Amivantamab Lazertinib in EGFR-Mutated Advanced NSCLC: Result…
Nov 14, 2023
targetedonc.com
The Role of Amivantamab Plus Lazertinib in EGFR NSCLC | OncLive
3 months ago
onclive.com
5:12
Subcutaneous Amivantamab Reshapes Frontline EGFR-Mutant …
589 views1 month ago
YouTubeOncUpdates: Latest Oncology Insights
Johnson & Johnson : Subcutaneous RYBREVANT®▼ (amivantamab) a…
2 months ago
marketscreener.com
8:58
Subcutaneous Amivantamab vs Intravenous Amivantamab, Both i…
Jun 25, 2024
onclive.com
Amivantamab Plus Lazertinib vs Osimertinib in First-Line EGFR-Mu…
Jun 19, 2024
onclive.com
3:22
Amivantamab in NSCLC: Interpreting MARIPOSA and Guide…
4 months ago
pharmacytimes.com
WCLC 2025 Insights: 1L Subcutaneous Amivantamab Che…
6 months ago
vumedi.com
2:15
Amivantamab is approved as second-line therapy for NSCLC wit…
1.6K viewsNov 30, 2023
FacebookThe New England Journal of Medicine
5:18
Expert video report on amivantamab in combination therapy for 1L trea…
2.4K viewsOct 30, 2023
YouTubeEuropean Society for Medical Oncology (ESMO)
1:11
Evaluating the benefits of subcutaneous amivantamab in EG…
143 viewsSep 25, 2024
YouTubeVJOncology
3:38
Updates from PAPILLON: 1L Amivantamab Chemotherapy in A…
Nov 14, 2023
targetedonc.com
1:02
Dr Reckamp on Amivantamab in EGFR Exon 20–Mutated NSCLC
415 viewsJul 27, 2024
YouTubeOncLive
Analyzing the MARIPOSA Overall Survival Data in the Frontline Trea…
1 year ago
onclive.com
ASCO® 2024 Insights: "CHRYSALIS-2 Trial - Amivantamab Lazertinib i…
84 viewsJun 14, 2024
vumedi.com
FDA Approval of Subcutaneous Amivantamab Is Significant Step F…
4 months ago
ajmc.com
2:54
New Insights From the MARIPOSA Trial: Amivantamab Plus Lazertini…
953 views10 months ago
YouTubeOncUpdates: Latest Oncology Insights
2:04
MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in E…
916 viewsOct 30, 2023
YouTubeVJOncology
16:45
Amivantamab in combination with lazertinib for osimertinib-relapsed…
1.8K viewsAug 4, 2021
YouTubeecancer
Navigating the New Treatment Options in the Frontline Managem…
Mar 14, 2025
onclive.com
3:21
Post-progression analysis of MARIPOSA-2: amivantamab + che…
479 viewsMay 10, 2024
YouTubeVJOncology
Dr Joshua Sabari Discusses Amivantamab’s First-Line Approv…
Mar 4, 2024
ajmc.com
1:10
Dr Besse on Mechanisms of Acquired Resistance in EGFR+ Ad…
166 viewsOct 5, 2024
YouTubeOncLive
See more videos
Static thumbnail place holder